肾移植术后3个月起依维莫司联合环孢素撤除或低暴露环孢素的多中心随机试验
这项前瞻性多中心随机12个月试验将499例新肾移植患者随机分为标准环孢素组、依维莫司替换环孢素组和依维莫司联合低剂量环孢素组。主要终点显示,无钙调磷酸酶抑制剂(CNI)组从随机化至12个月估计肾小球滤过率(eGFR)改善显著优于标准CNI组和低CNI组,而急性排斥发生率三组相似。
要点
- 肾移植术后3个月起采用依维莫司并撤除CNI可显著改善12个月肾功能。
- 无CNI组eGFR改善较标准CNI组平均差异5.6 mL/min/1.73 m²。
- 无CNI组与低CNI组急性排斥发生率相似,但药物不良事件导致停药率更高。
核心结论
- 肾移植术后3个月启动依维莫司并撤除CNI可在12个月时显著改善肾功能,且急性排斥发生率与标准CNI方案相似。
研究设计与样本
- 前瞻性、随机、多中心、12个月试验,纳入499例新肾移植患者,术后3个月随机分为标准CNI(环孢素)联合霉酚酸组、依维莫司联合霉酚酸组(无CNI)和依维莫司联合低剂量CNI且不用霉酚酸组。
主要发现
- 主要终点eGFR(Nankivell)从随机化至12个月的变化:无CNI组较标准CNI组平均差异5.6 mL/min/1.73 m²(95%CI 2.8-8.3,P<0.001)。
- 无CNI组eGFR改善亦优于低CNI组,平均差异5.5 mL/min/1.73 m²(95%CI 2.8-8.2,P<0.001);低CNI组与标准CNI组结果相似。
- 随机化后活检证实的急性排斥发生率:无CNI组11.7%,低CNI组8.1%,标准CNI组7.9%(无CNI vs 标准CNI P=0.27;低CNI vs 标准CNI P=1.00)。
- 不良事件导致研究药物停用率:无CNI组28.7%,低CNI组15.5%,标准CNI组15.2%。
临床怎么用
- 对于肾移植术后3个月的患者,可考虑采用依维莫司并撤除CNI以改善长期肾功能,但需警惕不良事件导致的停药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND.: Randomized trials have shown that early adoption of everolimus-based immunosuppressive regimens without a calcineurin inhibitor (CNI) improves long-term kidney graft function, but the optimal strategy for CNI minimization remains uncertain. METHODS.: In a prospective, randomized, multicentre, 12-month trial, 499 de novo kidney transplant patients were randomized at Month 3 to (i) remain on standard CNI (cyclosporine) therapy with mycophenolic acid, (ii) convert to everolimus with mycophenolic acid or (iii) start everolimus with reduced CNI and no mycophenolic acid (clinical trials registry: ClinicalTrials.gov-NCT00514514). RESULTS.: The primary endpoint, change in estimated glomerular filtration rate (eGFR) (Nankivell) from randomization to Month 12, was significantly greater in the CNI-free arm versus standard CNI therapy: mean difference 5.6 mL/min/1.73 m 2 [95% confidence interval (CI) 2.8-8.3 mL/min/1.73 m 2 , P < 0.001]. The improvement in eGFR in the CNI-free arm was also higher than in the low-CNI group (mean difference 5.5 mL/min/1.73 m 2 , 95% CI 2.8-8.2 mL/min/1.73 m 2 , P < 0.001), while results were similar in the low-CNI and standard CNI arms. The post-randomization incidence of biopsy-proven acute rejection was 11.7%, 8.1% and 7.9% in the CNI-free, low-CNI and standard CNI groups, respectively (CNI-free versus standard CNI, P = 0.27; low-CNI versus standard CNI, P = 1.00). Adverse events led to study drug discontinuation in 28.7%, 15.5% and 15.2% of CNI-free, low-CNI and standard CNI patients, respectively. CONCLUSIONS.: Everolimus initiation with CNI withdrawal at Month 3 after kidney transplantation achieves a significant improvement in renal function at 12 months, with a similar rate of acute rejection.
引用
- Budde K, Zeier M, Witzke O, et al. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrol Dial Transplant. 2017. PMID: 28605781. doi:10.1093/ndt/gfx075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。